EPTIS
BAM Logo

PML RARa

EPTIS factsheet 794262 | Last revision 2020-10-23 | URL: https://www.eptis.bam.de/pts794262 https://www.eptis.bam.de/pts794262

PT provider
PT provider RCPAQAP RCPAQAP
Based in Australia
Language(s) English
Remarks This module qualitatively assesses laboratory performance in the detection of Promyelocytic Leukaemia/Retinoic Acid Receptor Alpha (PML-RARa) fusion gene.
Keywords
Product groups Human test material
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
2µg of lyophilised, purified RNA PML-RARa fusion transcripts Molecular genetic testing
Aims of the PT scheme
Target group of participants
Linked to specific legislation / standards
Additional, subsidiary aims
Number of participants
Accredited or otherwise reviewed by a 3rd party
Operation is commissioned / requested by
Fees and frequency
Participation fee Yes
Regularly operated Yes (3 cases per survey/1 surveys)
Year of first operation
Contact details of the PT provider
Provider Contact person
RCPAQAP
Suite 201/8 Herbert Street
St Leonards, 2065
Australia

Phone: (61 2) 9045 6000
Fax: (61 2) 9356 2003
Web: https://www.rcpaqap.com.au/ https://www.rcpaqap.com.au/
Mr Rhys Judd
Phone: (61 2) 9045 6000
Fax: (61 2) 9356 2003
Email: rhys.judd@rcpaqap.com.au rhys.judd@rcpaqap.com.au
If you find any mistakes please contact the responsible EPTIS coordinator in Australia, Ms Luminita Antin. Ms Luminita Antin.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5